600518.SH
Kangmei Pharmaceutical Co., Ltd.
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 1.26
+0.00%Year over year
Reported trailing growth
- Revenue
- -4.8%
- EBITDA
- —
- EBIT
- +140.3%
- EPS
- —
- Free cash flow
- +73.1%
- Operating cash flow
- +180.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +7.9%
- EBITDA
- -8.7%
- EBIT
- -36.4%
- Net income
- -68.3%
- EPS
- -73.5%
- Free cash flow
- +78.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026